Effects of ziprasidone on serum cholinesterase concentration in schizophrenia patients
-
摘要: 目的 探讨齐拉西酮对精神分裂症患者血清胆碱酯酶浓度(CHE)浓度的影响。 方法 将126例精神分裂症患者随机分为观察组和对照组,观察组给予齐拉西酮治疗,对照组给予氯氮平治疗,进行阳性和阴性症状量表(PANSS)评定,并检测治疗后7、14、28 d的CHE浓度。 结果 ①治疗后观察组和对照组PANSS得分均有不同程度的降低,但对照组PANSS得分显著低于观察组[阳性症状:(15.3±4.7)vs(22.4±4.8),P<0.01;阴性症状:(14.6±4.5)vs(21.8±5.2),P<0.01;一般精神症状:(13.3±3.4)vs(19.2±3.9),P<0.01)]。②齐拉西酮或氯氮平治疗均能明显降低CHE的浓度;两种药物分别治疗28 d后,对照组CHE浓度较观察组明显降低[(8 339±2 106)vs(7 366±2 024),P<0.01]。③治疗中两组均有不良反应,观察组不良反应率为34.9%,对照组不良反应率为71.4%,组间比较有显著性差异(χ2=16 862,P<0.001)。 结论 齐拉西酮能对CHE活性有抑制作用,其抑制强度较氯氮平弱,从而可能使齐拉西酮对精神分裂症患者疗效低于氯氮平,但其安全性明显高于氯氮平。Abstract: Objective To explore the effects of ziprasidone and clozapine on serum cholinesterase (CHE) concentration in schizophrenia patients. Methods 126 schizophrenia patients were randomly divided into the observation group and the control group. The observation group was treated with ziprasidone. The control group received clozapine. The serum CHE concentration was assayed at 7, 14 and 28 days after treatment. Results ① The PANSS scores in both groups were significantly reduced after treatment, while the control group was lower than the observation group (PANSS score for positive symptoms:15.3±4.7 vs 22.4±4.8, P<0.01; negative symptoms:14.6±4.5 vs 21.8±5.2, P<0.01; general psychiatric symptoms:13.3±3.4 vs 19.2±3.9, P<0.01). ② CHE levels were decreased in both groups after treatment. The control group exhibited greater decrease than the observation group. ③ The observation group had lower adverse reaction rate (34.9%) compared to control group (71.4%). Conclusion ziprasidone has weaker inhibitory effect on CHE activity compared to clozapine. This may explain that ziprasidone has lower therapeutic efficacy and better safety profile.
-
Key words:
- ziprasidone /
- schizophrenia /
- serum cholinesterase
-
[1] 翟倩, 丰雷, 张国富. 精神分裂症患者的认知功能障碍探讨[J]. 浙江医学, 2019, 41(13):1367-1369, 1373 [2] SCHOOLER N R. Maintaining symptom control: review of ziprasidone long-term efficacy data[J]. J Clin Psychiatry,2003,64(Suppl 19):26-32 [3] 程波, 王燕, 周君亚. 阿立哌唑与利培酮治疗精神分裂症后抑郁的疗效及不良反应观察[J]. 临床研究, 2019(7):99-100 [4] POUGET J G, SHAMS T A, TIWARI A K, et al. Pharmacogenetics and outcome with antipsychotic drugs[J]. Dialogues Clin Neurosci,2014,16(4):555-566 [5] 顾琰颖, 张娟, 李国荣. 精神分裂症与抑郁症患者血清胆碱酯酶水平变化的探讨[J]. 浙江医学, 2015, 37(10):861-863 [6] 何燕玲, 张明园. 阳性和阴性综合征量表(PANSS)及其应用[J]. 临床精神医学杂志, 1997, 7(6):353-355 [7] 季乐新. 齐拉西酮与舒必利治疗精神分裂症的临床疗效比较分析[J]. 中国现代药物应用, 2015, 9(21):138-139 [8] 刘传芹, 李璐. 老年精神分裂症齐拉西酮与奥氮平治疗疗效及对血糖、血脂水平的影响[J]. 中国医药指南, 2019, 17(15):16-17 [9] 于长本, 赵德芬, 李金明, 等. 氯氮平、氯丙嗪对精神分裂症患者血清胆碱酯酶活力影响的研究[J]. 中国神经精神疾病杂志, 2002, 28(4):291-292 [10] 陈明艳. 非典型抗精神病药齐拉西酮的药代动力学、药效学及临床应用研究进展[J]. 中国医药指南, 2011, 9(17):52-53 [11] 范庆祝, 闵娟, 陈方斌. 冬眠灵及氯氮平治疗精神分裂症口涎量的比较[J]. 中国行为医学科学, 2003(3):340
计量
- 文章访问数: 4670
- HTML全文浏览量: 461
- PDF下载量: 2904
- 被引次数: 0